Article

UK-based Resurrect Bio has raised $8.1 million in an initial closing of its Series A funding round, following a seed round of $2.1 million in 2023. Led by Corteva through its Catalyst platform, the investment will accelerate product development and team expansion.

Resurrect Bio, spun out from The Sainsbury Laboratory in 2021, aims to restore plants' innate disease resistance by identifying protein interactions between crops and pathogens. The company is focusing on major crops like soy, corn, and wheat, with plans to deliver 18 disease resistance traits in the next three years.